Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates

Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also k...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Molly E., Sieben, Andrew J., Nelson, Kristin N., Kraay, Alicia N. M., Lopman, Ben, Handel, Andreas, Koelle, Katia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430602/
https://www.ncbi.nlm.nih.gov/pubmed/32817958
http://dx.doi.org/10.1101/2020.08.07.20170456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430602/
https://www.ncbi.nlm.nih.gov/pubmed/32817958
http://dx.doi.org/10.1101/2020.08.07.20170456

Ejemplares similares